|
KMID : 0380020210360020087
|
|
Korean Journal of Biotechnology and Bioengineering
2021 Volume.36 No. 2 p.87 ~ p.98
|
|
|
Antibody-Drug Conjugates: Development and Advances
|
|
Hong Yu-Dong
Kang Kyoung-Gon
Jung Jae-Youn
Ha Suk-Jin
Lim Kwang-Suk
|
|
|
Abstract
|
|
|
|
Biopharmaceutical drugs have strong therapeutic effect in various diseases such as autoimmune diseases, rheumatism and cancer due to their target specific recognition and low side effects. In particular, the most representative antibodies among biopharmaceuticals are widely used for targeted drug delivery, diagnosis and treatment. Moreover, antibody-drug conjugate (ADC) have been developed by many researchers and biopharmaceutical companies. An antibody-drug conjugate, one of the new bio anticancer drugs is composed of an antibody, cytotoxic drug and chemical linker. Antibodies accurately recognize the target cancer, and drugs induce apoptosis or death of the cancer cells. Linkers stably connects the antibody and drug until ADC go to the target cancer cells. In order to develop an ADC, it is important to correctly configure each component. Recently, the 9th ADC was approved by food and drug administration (FDA) and a lot of development of new ADC is underway. The development of ADC is expected through the introduction of new antibodies including bi-specific and drugs with new anticancer mechanisms.
|
|
|
KEYWORD
|
|
|
antibody-drug conjugate, antibody engineering, cancer immunotherapy, inhibitors, targeted delivery
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|